X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (301) 301
male (165) 165
hematology (162) 162
female (156) 156
adult (146) 146
middle aged (145) 145
aged (121) 121
index medicus (101) 101
oncology (94) 94
adolescent (59) 59
prognosis (53) 53
aged, 80 and over (46) 46
risk factors (44) 44
treatment outcome (38) 38
chemotherapy (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
non-hodgkins-lymphoma (35) 35
cancer (33) 33
immunology (33) 33
survival (31) 31
survival analysis (30) 30
follow-up studies (29) 29
therapy (29) 29
transplantation (28) 28
classification (27) 27
neoplasm staging (27) 27
expression (26) 26
disease (24) 24
cohort studies (23) 23
immunophenotyping (23) 23
lymphoma, non-hodgkin - pathology (23) 23
lymphomas (23) 23
retrospective studies (23) 23
young adult (23) 23
analysis (22) 22
care and treatment (22) 22
combined modality therapy (22) 22
lymphoma (22) 22
leukemia (21) 21
bone marrow - pathology (20) 20
non-hodgkin's lymphoma (20) 20
remission induction (20) 20
survival rate (20) 20
lymphoma, non-hodgkin - therapy (19) 19
medicine, general & internal (19) 19
peripheral vascular disease (19) 19
prednisone - administration & dosage (19) 19
risk (19) 19
prospective studies (18) 18
disease-free survival (17) 17
doxorubicin - administration & dosage (17) 17
mutation (17) 17
vincristine - administration & dosage (17) 17
antineoplastic agents - therapeutic use (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
bone marrow (16) 16
immunohistochemistry (16) 16
mantle cell lymphoma (16) 16
mastocytosis (16) 16
pathology (16) 16
time factors (16) 16
abridged index medicus (15) 15
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
cyclophosphamide - administration & dosage (15) 15
europe (15) 15
flow cytometry (15) 15
leukemia, hairy cell - pathology (15) 15
tumor cells, cultured (15) 15
health aspects (14) 14
translocation, genetic (14) 14
chronic lymphocytic-leukemia (13) 13
chronic myelogenous leukemia (13) 13
leukemia, hairy cell - immunology (13) 13
lymph nodes - pathology (13) 13
lymphoma, b-cell - pathology (13) 13
lymphoma, non-hodgkin - mortality (13) 13
medicine, research & experimental (13) 13
netherlands - epidemiology (13) 13
patients (13) 13
radiotherapy (13) 13
registries (13) 13
rituximab (13) 13
age factors (12) 12
animals (12) 12
b-lymphocytes - pathology (12) 12
dose-response relationship, drug (12) 12
follicular lymphoma (12) 12
hematology, oncology and palliative medicine (12) 12
interferon-alpha - therapeutic use (12) 12
karyotyping (12) 12
lymphoma, large b-cell, diffuse - pathology (12) 12
netherlands (12) 12
t-lymphocytes - immunology (12) 12
transplantation, autologous (12) 12
venous thromboembolism (12) 12
acute disease (11) 11
allergy (11) 11
cells, cultured (11) 11
cyclophosphamide (11) 11
incidence (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMBINATION | FLUDARABINE | STUDY-GROUP GLSG | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue 9, pp. 1691 - 1700
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2015, Volume 137, Issue 1, pp. 35 - 45
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 13, pp. 1338 - 1346
Journal Article
Journal Article